Journal
BLOOD
Volume 112, Issue 9, Pages 3671-3678Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-05-157016
Keywords
-
Categories
Funding
- BHCS Foundation
- DANA Foundation
- National Institutes of Health [U19 AI057234, U19 AI062623, AIO56001, CA78846]
Ask authors/readers for more resources
The development of novel human vaccines would be greatly facilitated by the development of in vivo models that permit preclinical analysis of human immune responses. Here, we show that nonobese diabetic severe combined immunodeficiency (NOD/SCID) beta(2) microglobulin(-/-) mice, engrafted with human CD34(+) hematopoietic progenitors and further reconstituted with T cells, can mount specific immune responses against influenza virus vaccines. Live attenuated trivalent influenza virus vaccine induces expansion of CD8(+) T cells specific to influenza matrix protein (FluM1) and nonstructural protein 1 in blood, spleen, and lungs. On ex vivo exposure to influenza antigens, antigen-specific CD8(+) T cells produce IFN-gamma and express cell-surface CD107a. FluM1-specific CD8(+) T cells can be also expanded in mice vaccinated with inactivated trivalent influenza virus vaccine. Expansion of antigen-specific CD8(+) T cells is dependent on reconstitution of the human myeloid compartment. Thus, this humanized mouse model permits preclinical testing of vaccines designed to induce cellular immunity, including those against influenza virus. Furthermore, this work sets the stage for systematic analysis of the in vivo functions of human DCs. This, in turn, will allow a new approach to the rational design and preclinical testing of vaccines that cannot be tested in human volunteers. (Blood. 2008; 112: 3671-3678)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available